Select your Market
-
- Algeria
- Angola
- Benin
- Botswana
- Burkina Faso
- Burundi
- Cameroon
- Cape Verde
- Central African Republic
- Chad
- Comoros
- Congo
- Congo Democratic Republic
- Djibouti
- Egypt
- Equatorial Guinea
- Eritrea
- Ethiopia
- Gabon
- Gambia
- Ghana
- Guinea
- Guinea-Bissau
- Ivory Coast
- Kenya
- Lesotho
- Liberia
- Libya
- Madagascar
- Malawi
- Mauritania
- Mauritius
- Morocco
- Mozambique
- Namibia
- Niger
- Nigeria
- Reunion Islands
- Rwanda
- Saint Helena
- São Tomé and Príncipe
- Senegal
- Seychelles
- Sierra Leone
- Somalia
- South Africa
- Sudan
- Swaziland
- Tanzania
- Togo
- Tunisia
- Uganda
- Zambia
- Zimbabwe
-
- Albania
- Austria
- Baltic Region
- Belarus
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Netherlands
- North Macedonia
- Norway
- Poland
- Portugal
- Romania
- Russian Federation
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Türkiye
- Ukraine
- United Kingdom
It’s a great idea to invest in us – and here’s why
- A trusted brand with leading positions in growth markets and robust trajectory.
- Operating across the entire value chain of life science-related industries.
- Bundle and integrate capabilities to increase speed and scalability.
- Source external innovation and capabilities where needed.
- Unlock value creation through higher revenue growth at attractive margins.

Related News
View All News-
Press Releases
Merck KGaA, Darmstadt, Germany Collaborates with NVIDIA, Microsoft and Dawn ...
Collaboration between with NVIDIA, Microsoft and Dawn Health to explore how AI-facilitated technology can help build an innovative model for PSPs.
2026/10/21
-
Press Releases
Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening ...
We enter into a definitive agreement to acquire biotechnology company Silence Therapeutics, focused on siRNA-therapies in areas of high unmet need.
2026/10/19
-
Press Releases
Merck KGaA, Darmstadt, Germany, to Present 25 Abstracts at ESMO 2026 Highlighting ...
The Company announced today that 25 abstracts from its oncology and rare tumor portfolios have been accepted for presentation at ESMO 2026 Congress.
2026/10/19
-
Share Price
Check Share PriceOur interactive Share Price Tool provides you with all the information you need. You can retrace our development within the last ten years or follow it in real time – or compare our share price to various indices. -
Financials
Read MoreOur Financial Reporting Center offers you the opportunity to select from financial data on an annual or quarterly basis.